Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27675172 | 0.89 | TDP1 (0.44) | ABCB1ABCG2LMNAHTTEGFR | |
| SCHEMBL2908569 | 0.85 | NPC1 (0.43) | ABCG2LMNAHTTEGFRTDP1 | |
| SCHEMBL16160281 | 0.83 | KMT2A (0.49) | LMNAHTTTDP1SMN1; SMN2NPC1 | |
| SCHEMBL26926495 | 0.81 | AKR1C3 (0.51) | LMNAHTTTDP1NPC1RAB9A | |
| SCHEMBL2190706 | 0.78 | HIF1A (0.55) | ABCB1ABCG2EGFRSLC7A5RAB9A | |
| SCHEMBL7504783 | 0.77 | ALDH1A1 (0.49) | ABCB1ABCG2EGFRSLC7A5SMN1; SMN2 | |
| SCHEMBL13662621 | 0.77 | PPARA (0.49) | LMNAEGFRSLC7A5ALDH1A1KMT2A | |
| SCHEMBL3261455 | 0.76 | ADRA1A (0.56) | LMNATDP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8341341 | 0.76 | SLC7A5 (0.51) | ABCB1ABCG2EGFRSLC7A5NPC1 | |
| SCHEMBL13641732 | 0.76 | MEN1 (0.52) | LMNAEGFRSLC7A5SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
| EP-1692109-B1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS | MEMORY PHARM CORP (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | MEMORY PHARMACEUTICAL CORPORATION | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222207-A1 | Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs | PDE4A, PDE4B, PDE3B | ABCB1 829/4885ABCG2 1543/4885LMNA 2705/4885 |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ABCB1 931/4885ABCG2 1335/4885LMNA 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.